Clinical Trials for Mesothelioma Patients—Sorafenib, Pemetrexed, and Cisplatin: Outcome Measures: Prior Concurrent Therapy

Read about the concurrent therapy for a current clinical trial about the use of Sorafenib, Pemetrexed, and Cisplatin for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only

Prior Concurrent Therapy:

• At least 3 weeks since prior systemic therapy (6 weeks for bevacizumab) and recovered
  
• At least 3 months since prior pemetrexed disodium or cisplatin
  
• No prior sorafenib tosylate
  
• More than 4 weeks since prior major surgery or open biopsy
  
• No NSAIDs or salicylates for 2 days before, during, and for 2 days after pemetrexed disodium administration
  
• No NSAIDs or salicylates with a long half-life (e.g., naproxen, piroxicam, diflunisal, albumetone) for 5 days before, during, and for 2 days after pemetrexed disodium administration
  
• No concurrent Hypericum perforatum
  
• Concurrent anti-coagulation treatment with warfarin or heparin allowed

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

Weitz & Luxenberg is a leading plaintiffs' law firm that has represented people affected by mesothelioma for over 20 years. Men and women diagnosed with mesothelioma caused by asbestos exposure may be entitled to compensation from the companies responsible for their disease. If you would like a free consultation or more information about your legal options, please complete the form below, and a representative of our law firm will contact you as soon as possible.